Skip to main content
Midas Edge

Vera Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

VERA$30.03-1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity

(in thousands, except share amounts)

Class A Common Stock · AdditionalPaid-in · Accumulated Other · Accumulated · TotalStockholders’
SharesAmountCapitalComprehensive Income (Loss)DeficitEquity
Balances as of December 31, 202344,452,161$44$410,492$251$(309,102)$101,685
Issuance of common stock from underwritten follow-on offering, net of offering costs9,274,1949269,583——269,592
Issuance of common stock pursuant to exercise of options708,89716,612——6,613
Issuance of common stock upon vesting of restricted stock units938—————
Issuance of common stock pursuant to employee stock purchase plan21,181—298——298
Proceeds from short swing settlement——37——37
Stock-based compensation——4,124——4,124
Unrealized gain (loss) on marketable securities———(424)—(424)
Net loss————(28,383)(28,383)
Balances as of March 31, 202454,457,371$54$691,146$(173)$(337,485)$353,542
Issuance of common stock pursuant to exercise of options358,26513,438——3,439
Issuance of common stock upon vesting of restricted stock units937—————
Stock-based compensation——4,873——4,873
Unrealized gain (loss) on marketable securities———(277)—(277)
Net loss————(33,708)(33,708)
Balances as of June 30, 202454,816,573$55$699,457$(450)$(371,193)$327,869
Issuance of common stock pursuant to exercise of options100,628—505——505
Issuance of common stock upon vesting of restricted stock units105,597—————
Issuance of common stock pursuant to employee stock purchase plan7,763—247——247
Repurchase of common stock(4,450)—(13)——(13)
Stock-based compensation——5,588——5,588
Unrealized gain (loss) on marketable securities———1,494—1,494
Net loss————(46,632)(46,632)
Balances as of September 30, 202455,026,111$55$705,784$1,044$(417,825)$289,058
Class A Common Stock · AdditionalPaid-in · Accumulated Other · Accumulated · TotalStockholders’
SharesAmountCapitalComprehensive Income (Loss)DeficitEquity
Balances as of December 31, 202227,800,861$28$290,216$(224)$(213,112)$76,908
Issuance of common stock from underwritten follow-on offering, net of offering costs16,428,57216107,727——107,743
Issuance of common stock pursuant to exercise of options3,750—65——65
Issuance of common stock pursuant to employee stock purchase plan27,926—175——175
Stock-based compensation——2,667——2,667
Unrealized gain (loss) on marketable securities———220—220
Net loss————(30,069)(30,069)
Balances as of March 31, 202344,261,109$44$400,850$(4)$(243,181)$157,709
Issuance of common stock pursuant to exercise of options44,820—432——432
Issuance of common stock upon vesting of restricted stock units2,500—————
Stock-based compensation——2,682——2,682
Unrealized gain (loss) on marketable securities———(138)—(138)
Net loss————(20,162)(20,162)
Balances as of June 30, 202344,308,429$44$403,964$(142)$(263,343)$140,523
Issuance of common stock pursuant to exercise of options45,078—197——197
Issuance of common stock upon vesting of restricted stock units62,884—————
Issuance of common stock pursuant to employee stock purchase plan16,554—101——101
Stock-based compensation——2,923——2,923
Unrealized gain (loss) on marketable securities———67—67
Net loss—$—$—$—$(20,104)$(20,104)
Balances as of September 30, 202344,432,945$44$407,185$(75)$(283,447)$123,707
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.